In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 2889-2894

  Wiesner, Jochen ^a   Henschker, Dajana ^a   Hutchinson, David B ^a   Beck, Ewald ^a   Jomaa, Hassan ^a  

^a Jomaa Pharmaka GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISIN; ATOVAQUONE; AZITHROMYCIN; BENFLUMETOL; CHLOROQUINE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; FOSMIDOMYCIN; HALOFANTRINE; LINCOMYCIN; LINCOSAMIDE DERIVATIVE; MEFLOQUINE; PROGUANIL; QUININE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VINCKEI; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FOSFOMYCIN; HUMANS; MALARIA; MICE; PLASMODIUM FALCIPARUM;

EID: 0036720273     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.2889-2894.2002     Document Type: Article

References (28)

1. Antimalarial activity of 77 phospholipid polar head analogs: Close correlation between inhibition of phospholipid metabolism and in vitro Plasmodium falciparum growth
2. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil
3. Interactions of atovaquone with other antimalarial drugs against Plasmodium falcipurum in vitro
4. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique
5. Clindamycin: A review of fifteen years of experience
6. A plastid organelle as a drug target in apicomplexan parasites
7. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs
8. Clindamycin
9. A plastid of probable green algal origin in Apicomplexan parasites
10. Clindamycin in malaria treatment
11. Curing of chloroquine-resistant malaria with clindamycin
12. Clindamycin treatment of falciparum malaria in Brazil
13. Fosmidomycin, a new phosphonic acid antibiotic. Part II. 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies
14. Fosmidomycin: A new phosphonic acid antibiotic. Part I. Phase I tolerance studies
15. Fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway of isoprenoid biosynthesis
16. Antibacterial activity and pharmacokinetics of clindamycin
17. Malarone (atovaquone and proguanil hydrochloride): A review of its clinical development for treatment of malaria
18. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation
19. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics
20. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria
21. Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity
22. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants
23. Clindamycin
24. Human malaria parasites in continuous culture
25. Pharmacokinetics and metabolism of fosmidomycin, a new phosphonic acid, in rats and dogs
26. Artemisinin and derivatives in the treatment of uncomplicated malaria
27. Plasmodium falciparum: Detection of the deoxyxylulose 5-phosphate reductoisomerase activity
28. Inhibition of the non-mevalonate 1-deoxy-D-xylulose-5-phosphate pathway of plant isoprenoid biosynthesis by fosmidomycin